(NASDAQ: AVTX) Avalo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.
Avalo Therapeutics's earnings in 2025 is -$99,878,000.On average, 11 Wall Street analysts forecast AVTX's earnings for 2025 to be -$105,523,373, with the lowest AVTX earnings forecast at -$132,040,675, and the highest AVTX earnings forecast at -$26,656,933. On average, 11 Wall Street analysts forecast AVTX's earnings for 2026 to be -$85,331,200, with the lowest AVTX earnings forecast at -$132,929,239, and the highest AVTX earnings forecast at -$35,225,233.
In 2027, AVTX is forecast to generate -$74,033,738 in earnings, with the lowest earnings forecast at -$121,555,614 and the highest earnings forecast at -$43,983,939.